Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
Recent positive momentum driven by new product launches and analyst coverage is likely to sustain investor interest in the near term.
Jefferies initiated coverage of Alpha Teknova on September 17, 2026, with a Buy recommendation. This analyst action serves as a positive signal for institutional investor sentiment.
NasdaqAlpha Teknova introduced the Fill-Tek Dispensing System on September 16, 2026, a proprietary technology for single-use bag filling. The system is designed to improve manufacturing flexibility and efficiency, potentially enhancing the company's competitive position in the biopharmaceutical reagent market.
Alpha Teknova Press ReleaseAlpha Teknova is scheduled to participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026. Such events often provide a platform for management to update investors on business progress and strategic initiatives.
Alpha Teknova Investor Relations